Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)

Key Points DNMT3A mutations are frequent in younger adults with AML and have no significant impact on survival end points. Only moderate effects on outcome, depending on molecular subgroup and DNMT3A mutation type, could be observed.